ERBB2 and cardiotoxicity: During the period of neoadjuvant dual anti-HER2 therapy, 6.8% of patients experienced a decline of ≥10 percentage points in LVEF relative to the baseline and an absolute decrease to less than 50% simultaneously, which was defined as cardiotoxicity (Figure 3A).